The interaction of medications used in palliative care

Hematology/Oncology Clinics of North America

Volumn 16, Issue 3, 2002, Pages 641-655

  Bernard, Stephen A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORFLUOXETINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN; ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; PSYCHOTROPIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

CANCER PALLIATIVE THERAPY; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; REVIEW; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NEOPLASM; PALLIATIVE THERAPY; PHYSIOLOGY;

ANALGESICS; ANTIBIOTICS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMAN; METABOLIC CLEARANCE RATE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS; PALLIATIVE CARE; POLYMORPHISM (GENETICS); PSYCHOTROPIC DRUGS; ANTI-BACTERIAL AGENTS; HUMANS; POLYMORPHISM, GENETIC;

EID: 0036021429     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00014-X     Document Type: Review

References (90)

1. Principles of therapeutics
2. Clinical and pharmacoeconomic significance of metabolic drug interactions
3. Interactions and drug-metabolizing enzymes
4. Antidepressant drug interactions and the cytochrome P450 system
5. Cytochromes P450: Historical overview
6. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients
7. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450
8. CYP3A activity in African Americans and European American men: Population differences and functional effect of the CYP3A4 * 1B5′-promoter region polymorphism
9. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants
10. Drug interactions and the cytochrome P450 system
11. Metabolism of drugs by cytochrome P450 3A isoforms: Implications for drug interactions in psychopharmacology
12. UDP-glucuronyltransferases
13. Does P-glycoprotein play a role in anticancer drug pharmacokinetics?
14. Increased drug delivery to the brain by P-glycoportein inhibition
15. Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the induction phase
16. Interactions in the elderly
17. Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits
18. Drug-drug interactions involving antidepressants: Focus on venlafaxine
19. P450 enzyme: Inhibition mechanisms, genetic regulation,and effects of liver disease
20. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal
21. Use of in vitro human metabolism studies in drug development
22. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects
23. Treating depression: Potential drug-drug interactions
24. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
25. Molecular genetics of the derisoquin-sparteine polymorphism
26. Sparteine metabolism in Canadian caucasians
27. Pharmacogenetics of antidepressants: Clinical aspects
28. Low frequency of dextromethorphan O-demethylation in a Chinese population
29. Pharmacokinetics of dextromethorphan and dextrorphan: A single dose comparison of three preparations in human volunteers
30. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions
31. Bupropion plasma levels and CYP2D6 phenotype
32. The serotonin syndrome
33. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation
34. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
35. Desipramine hydroxylation: Variability and effect of antipsychotic drugs
36. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse
37. Are pharmacokinetic drug interactions with the SSRI's an issue?
38. Inhibition of fluoxetine of cytochrome P450 2D6 activity
39. Pharmacogenetics and drug metabolism of newer antidepressant agents
40. Elevated antidepressant plasma levels after addition of fluoxetine
41. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
42. Tricyclic antidepressant plasma levels after fluoxetine addition
43. Adverse interactions encountered when using trazodone to treat insomnia asociated with fluoxetine
44. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine
45. Tardive dyskinesia in a patient taking haloperidol and fluoxetine
46. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine
47. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors
48. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP 2D6) activity in human liver microsomes
49. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor
50. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
51. Fluvoxamine: A review of global drug-drug interaction
52. Commonly prescribed medications in advanced cancer patients
53. Substantial rise in sparteine metabolic ratio during haloperidol treatment
54. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man
55. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype
56. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
57. Phenytoin-induced methadone withdrawal
58. Cabramazepine metabolism in man: Induction and pharmacogenetic aspects
59. Toxic serotonin syndrome after fluoxetine plus carbamazepine
60. Pharmacokinetic interactions of the new antiepileptic drugs
61. Case report: Interaction of rifampin and nortriptyline
62. Macrolide antibacterials. Drug interactions of clinical significance
63. Drug interactions with the non-sedating antihistamines
64. Protease ihibitors in patients with HIV disease. Clinically important pharmacokinetic considerations
65. Clinical pharmacokinetics of alfentanil, fentanyl, and sufentanil
66. Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil
67. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4
68. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone
69. Methadone in the management of cancer pain: A review
70. Disposition of narcotics and narcotic antagonists
71. Probable metabolic interaction between methadone and fluvoxamine in addict patients
72. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immuno-identified cytochrome P-450IIDI
73. The influence of pharmacogenetics on opioid analgesia: Studies with codeine and ocycodone in the Sprague-Dawley/Dark Agouti Rat Model
74. Polymorphic O-demethylation of codeine
75. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions
76. The pharmacokinetics of oxycodone after intravenous injection in adults
77. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone
78. Antidepressants increase bioavailability of morphine in cancer patients
79. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
80. The polymorphic metabolism of dextromethorphan
81. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor mediated neurotoxicity on cortical neurons
82. Dextromethorphan inhibits NMDA-induced convulsions
83. Possible lethal reaction between nardil and dextromethorphan
84. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid
85. Synergistic analgesic interaction of morphine with dextromethorphan, an NMDA receptor antagonist in oral surgery
86. Premedication with oral dextromethorphan reduces postoperative pain after tonsillectomy
87. Superior analgesic activity of morphine with dextromethorphan, an NMDA receptor antagonist in oral surgery pain
88. Combined opioid-NMDA antagonist therapies
89. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19